| INTRODUCTION
The current goals of novel therapeutics for the treatment of Crohn's disease and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD), are to induce and maintain steroid-free remission and achieve long-term mucosal healing, so as to reduce/eliminate the need for IBD-related hospitalisation and surgery, improve patient quality of life and avoid disability. [1] [2] [3] The current standard of care includes 5-aminosalicylates (5-ASAs), which are used as first-line therapy for UC. However,~50% of patients do not respond to 5-ASAs alone and require more aggressive intervention with corticosteroids and/or immunosuppressant therapy (eg azathioprine, mercaptopurine and methotrexate). Corticosteroid and immunosuppressant therapies, however, are often associated with significant side effects or intolerance and may have limited efficacy; for example, corticosteroids have not shown benefit in the maintenance settings. 4, 5 In patients who do not achieve or maintain remission in response to corticosteroids or immunosuppressants, biologic therapy options including monoclonal antibodies (mAbs) targeting tumour necrosis factor a (TNF-a), such as infliximab (Remicade, Janssen Biotech Inc.,
Horsham, PA, USA) and adalimumab (Humira, AbbVie, Chicago, IL, USA), can be used to induce and maintain remission. 6, 7 Overall, the benefit-risk profiles for anti-TNF-a biologics are considered acceptable. However, approximately 10%-30% of IBD patients are primary nonresponders to anti-TNF-a therapy, and another approximately 20%-40% of IBD patients stop responding to anti-TNF-a therapy over time. 8, 9 In addition, these TNF-a inhibitors are associated with increased risk of infections and IBD-related complications stemming from inadequate disease control. [10] [11] [12] In addition to offering better benefit-risk profiles, new innovative and effective therapies will also positively influence the balance of cost-effectiveness by lowering healthcare utilisation, given that IBD was the primary cause for 1.36 and 1.9 million physician visits per year in the United States in 2004 and 2009, respectively, and the first-listed discharge diagnosis in over 100 000 hospitalisations. 13 Hence, there continues to be a need for novel treatments with improved benefit-risk profiles that enhance the long-term prognosis of patients with IBD.
Binding of integrins to their ligands controls leucocyte trafficking and retention within peripheral tissues, such as the gut, and modulates the local inflammatory milieu; thus, integrins are emerging therapeutic targets for the treatment of IBD. Natalizumab (anti-a4 integrin; Tysabri, Biogen, Cambridge, MA, USA) is approved for
Crohn's disease in the United States, 14 whereas vedolizumab (an anti-integrin mAb targeting a4b7 heterodimers; Entyvio, Takeda, Osaka, Japan) is on the market for the treatment of both UC and
Crohn's disease. 15, 16 Etrolizumab (also called rhuMAb b7; Genentech, San Francisco, CA, USA), currently under evaluation in clinical studies for its therapeutic potential in IBD, is an IgG1-humanised monoclonal antibody that specifically targets the b7 subunit of both the a4b7 and aEb7 integrins. Binding to b7 integrin enables etrolizumab to block both leucocyte trafficking to the gut via a4b7 interactions with its endothelial ligand mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), 17, 18 expressed primarily on endothelium of venules of intestinal lamina propria and associated lymphoid tissues 19, 20 as well as the retention of lymphocyte subsets within the intestinal mucosa through the interaction of aEb7 with its ligand E-cadherin, expressed on the gut epithelium 21 ( Figure 1 , Table 1 ). [22] [23] [24] [25] The objectives of this review are to summarise the available published and unpublished nonclinical and clinical pharmacological, pharmacokinetic (PK) and pharmacodynamic (PD) data for etrolizumab, and to provide a comprehensive understanding of its mechanism of action (MOA) and pharmacological effects. Since etrolizumab has a unique dual MOA associated with inhibition of both the a4b7 and aEb7 pathways, the integrated pharmacological information summarised in this review aims to provide researchers and investigators with a clear view of its unique biology distinct from other anti-integrin drugs in the class.
| The role of b7 integrins and their ligands
Integrins are cell surface glycoprotein receptors that play a role in a wide range of cell-cell and cell-matrix interactions during embryogenesis, thrombosis and leucocyte adhesion, signalling, proliferation and migration. 26 They are composed of heterodimeric, noncovalently interacting a and b subunits that bind distinct cell adhesion molecules (CAMs) on endothelia, epithelia and the extracellular matrix.
This review focuses on leucocyte homing mediated by integrin binding to tissue-specific CAMs to regulate cell recruitment from the peripheral circulation into tissues.
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a4b7 integrin plays a crucial role in leucocyte homing to the intestinal mucosa and associated lymphoid tissues. a4b7 integrin is constitutively expressed at a modest level on naive T and B cells and at higher levels on intestinal-homing effector/memory T and B cells.
In contrast, effector/memory T and B cells that are activated to home to nonintestinal tissue express low levels of a4b7 integrin.
Additionally, a4b7 integrin is also expressed on NK cells, stimulated monocytes, macrophages, mast cells, eosinophils and basophils. 26, 28, 29 In the gut, firm adhesion of leucocytes to the mucosal endothelium is initiated by chemokine signals which induce a conformational change in the a4b7 heterodimer on leucocytes that enable binding to MAdCAM-1 with high affinity. This engagement slows leucocyte movement along the endothelial surface, eventually arresting the cell before extravasation through the vascular endothelium to underlying tissue. 27 T lymphocytes bearing a4b7 preferentially bind to endothelial venules expressing MAdCAM-1 in intestinal tissue as well as to the extracellular matrix molecule fibronectin fragment CS-1. [30] [31] [32] The endothelial cell surface protein vascular cell adhesion molecule-1 (VCAM-1) also interacts with a4b7, albeit with a slightly lower affinity compared with its interaction to MAdCAM- Gut epithelium Lamina propria F I G U R E 1 Etrolizumab mechanism of action. Etrolizumab has a dual mechanism of action, inhibiting both a4b7:MAdCAM-1-mediated lymphocyte trafficking to the gut mucosa (arrow #2) and aEb7:E-cadherin-mediated lymphocyte retention in the intraepithelial space (arrow #1). IEL, intraepithelial lymphocytes; VCAM-1, vascular cell adhesion molecule 1; MAdCAM-1, mucosal vascular addressin cell adhesion molecule 1 aE supports a distinct role for this integrin in mucosal immunology. 36, 37 aE expression has also been described on dendritic cells, mast cells 28 and innate lymphoid cells (ILCs). 38 The aE integrin is only known to dimerise with the b7 integrin, a process critical for the translocation of aEb7 to the cell surface to enable cell binding to E-cadherin. 21 Etrolizumab is a humanised mAb derived from the rat anti-mouse/human b7 mAb FIB504. 55 The humanised version of FIB504 antibody, (Table 3 ). These data indicate that etrolizumab is potent in inhibiting in vitro adhesion of a4b7 + bearing cells to human MAdCAM-1 or VCAM-1.
In addition, etrolizumab is highly specific for the b7 subunit of a4b7 and aEb7 and does not bind to a4 or b1 integrin subunits.
Experiments with a4b1 the inflamed colon but had no effect on lymphocyte homing to the spleen. 56 This supports the hypothesis that etrolizumab specifically blocks lymphocyte homing to the inflamed GI tract and has no apparent effect on lymphocyte trafficking to peripheral lymphoid tissues.
In addition, studies in cynomolgus monkeys demonstrated that animals dosed with etrolizumab increased their peripheral blood b7 High CD45RA À "gut homing memory" CD4 + T lymphocytes but had no substantial effect on b7 Low CD45RA À "peripheral homing memory" CD4 + T lymphocytes or b7 Intermediate CD45RA + naive CD4 + T-helper lymphocytes. 56 The increase in peripheral b7 High lymphocytes, presumably due to the inhibition of the trafficking mechanisms of these cells to gut tissue, correlated with the complete peripheral cell b7 receptor occupancy (RO) by etrolizumab. Subsequent washout of etrolizumab from the circulation led to the loss of complete b7 RO and the recovery of peripheral b7 High lymphocytes towards baseline levels. 56 Furthermore, in etrolizumab-dosed cynomolgus monkeys and mice, dose-dependent and reversible decrease in lymphocytes in the GI-associated lymphoid tissue (GALT) in cynomolgus monkeys and the intestinal lamina propria in mouse were observed by semi-quantitative histological evaluation. 57 No changes in lymphocyte numbers were observed in any non-gut tissues, including the central nervous system (CNS). Importantly, despite the decrease in intestinal lymphocytes, there was no evidence of GI tract infections or any other adverse finding in either species, indicating that the observed pharmacological effect of etrolizumab on the GI tract was without any associated toxicological effects.
Treatment with the anti-a4b1 integrin antibody natalizumab has been associated with an increased risk of progressive multifocal by the John Cunningham virus. Thus, leucocyte homing to the CNS has been deemed an important safety consideration. 58 Accordingly, a myelin basic protein/T-cell receptor (MBP-TCR) transgenic mouse model of experimental autoimmune encephalomyelitis (EAE) was used to assess the potential effect of the murine anti-b7 mAb muFIB504 on lymphocyte homing to the CNS. While muFIB504 had no effect on EAE disease severity as assessed by leucocytic infiltration into the CNS or improvement of survival, the murine anti-a4
antibody (mPS/2) significantly decreased leucocytic infiltration into the CNS and reduced EAE disease severity and death. 56, 57 These data clearly demonstrate that the a4b7 integrin is not involved in inflammatory cell recruitment across the blood-brain barrier, while the a4b1 integrin is. 57, 59 In addition, in other models of chronic CNS inflammation, CD4 + memory T-lymphocyte infiltrates in the CNS do not express a4b7, a6 or aE integrin but instead, strongly express a4b1. and 10% in the 300 mg+LD cohort (n = 39), compared with 0% in the placebo cohort (n = 41); but the majority of patients achieving clinical remission (83%) were from the TNF-naive population. Among TNF-naive patients, 44% in the 100 mg cohort (n = 16) and 25% in the 300 mg + LD cohort (n = 12) were in clinical remission at 10 weeks compared with 0% of patients in the placebo cohort (n = 15). 24 UC patients in EUCALYPTUS were allowed to cross over into an OLE study (SPRUCE, ClinicalTrials.gov: NCT01461317) in which 108 patients were treated with etrolizumab for a median of 6.9 months (range: 0.8-54.3 months).
Overall rates of adverse events (AEs) in the etrolizumab-treated patients of the EUCALYPTUS study were similar to those in the placebo arm. 24 Notably, rates of infections were similar among all groups. Mild injection site reactions (ISRs) were reported in the 300 mg+LD cohort, but no severe hypersensitivity reactions were seen. Mean PK parameters for clearance and central volume of distribution were similar across the different doses, with a relatively shorter terminal half-life at dose levels ≤0.5 mg/kg, which could be attributed to target-mediated clearance at lower dose levels. Moderate drug accumulation was observed in patients who received multiple doses in the phase I study (accumulation ratio for AUCs of approximately 1.2-fold for IV and 2.2-fold for SC doses). 65 In the phase II EUCA-LYTPUS study, linear PK profiles were observed in both treatment arms, with a similar time to maximum concentrations (T max ) of approximately 5-6 days after both the first and the last doses. Based on mean C max after last dose (C max,last dose ) and AUCs (days 56-84) , the drug exposure in the 300 mg + LD dose group was approximately 4.3-to 4.6-fold higher than that of the 100 mg dose group. The 300 mg + LD dose group also showed a 4-fold higher drug concentration than that of the 100 mg arm at the primary efficacy endpoint time at week 10. were not found to have significant impact on etrolizumab PK parameters. 66 This population PK model will be refined pending additional data from ongoing phase III studies.
| Pharmacodynamics
Binding of etrolizumab to b7 integrin receptors on the surface of circulating lymphocytes was evaluated by flow cytometry in both phase I and phase II EUCALYPTUS studies. Complete or near-complete occupancy of b7 integrin receptors on circulating b7 High intestinal homing T and B lymphocytes was observed as early as day 2 following etrolizumab dosing. This rapid RO in the peripheral blood was observed in all dose levels (0.3-10 mg/kg IV, 0.5-3.0 mg/kg SC and 100 or 300 mg + LD SC doses) evaluated, but the duration of complete RO was dose dependent during the drug washout period in etrolizumab-treated patients. 24, 65 Furthermore, a consistent PK/PD relationship was observed across etrolizumab-treated cohorts, with a minimum etrolizumab serum concentration range of 1-3 lg/mL deemed necessary for full b7 RO on circulating b7
High CD45RA À intestinal homing T cells. 65 Consistent with b7 RO in peripheral blood, complete drug occupancy of both a4b7 and aEb7 receptors was observed in T lymphocyte subsets in colonic biopsy tissues from etrolizumab-treated patients.
As expected, there was no b7 RO in peripheral blood or in colonic sies achieved a more than 2-fold higher clinical remission rate at 10 weeks compared with patients with low aE gene expression. 24 Similar heterogeneity in efficacy outcomes has been observed in studies using other therapies (eg anti-TNFa), suggesting a molecular and/or pathophysiological heterogeneity among patients with IBD.
Efforts to understand this heterogeneity and more precise identification of patient subsets based on biomarkers such as aE may increase the likelihood of predicting clinical benefit. The current hypothesis is that patients who express aE at higher levels in their inflamed gut tissue may have an increased likelihood of achieving clinical benefit (eg achieving remission or response) with etrolizumab treatment. A careful evaluation of this hypothesis is underway during the ongoing phase III studies.
| PK/PD modelling outcome
The serum etrolizumab concentration-time profile and the time profile of peripheral blood cells with free b7 receptors (available for ligand binding) from the phase I study were simultaneously modelled using a quasi-steady-state (QSS) target-mediated drug disposition (TMDD) model. 67 The final QSS TMDD model adequately described the time profiles of both serum-free etrolizumab concentrations and peripheral T cells with free b7 receptor (% baseline [BL]) in UC patients with reasonable precision, as the relative standard error values of all parameter estimations were ≤15%.
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The relationship between free serum etrolizumab concentration and peripheral T cells with free b7 receptors (% BL) was constructed using simulated PK/PD data generated by this model, and the median EC 90 value for peripheral T cells b7 RO (90% of baseline level)
with etrolizumab was estimated as 1.3 lg/mL. The phase II EUCA-LYPTUS study dosing regimens were designed based on this estimated EC 90 concentration. The observed PK/PD profiles in the EUCALYPTUS study were in agreement with the model prediction (Figure 4) , 67 and the low-dose 100 mg SC q4w regimen was shown to be sufficient to fully occupy peripheral blood b7 receptors (reaching maximal pharmacological effect) in all of the treated UC patients.
This dose level also demonstrated full RO in colonic biopsy tissues and clinically meaningful improvement over placebo by inducing clinical remission in patients with moderately to severely active UC.
Consistent with maximised pharmacological effect at the lower 100 mg q4w dose, the higher dose regimen (300 mg + LD) did not demonstrate additional clinical benefit. 24 
| Exposure-response analysis
In the phase II EUCALYPTUS study, an exposure-response (E-R) relationship was evaluated using drug concentration quartile and clinical remission (at the primary endpoint). No E-R correlation was observed in this study. Although clinical remission based on the full MCS scores showed a numerically lower remission rate in the high-dose (300 mg + LD) cohort in all patients, this "inverse E-R relation" was not apparent when examining endoscopic remission rate (endoscopic score ≤1). expressing T lymphocytes observed in both low-and high-dose groups. 24, 67, 69 The lack of an E-R relationship, where "response" was either clinical readouts or PD changes, is consistent with the finding that maximal pharmacological effects were achieved in both low (100 mg q4w)-and high (300 mg + LD)-dose groups, suggesting that both dose regimens reached the plateau portion of the E-R curve.
Given that all patients evaluated in the phase II EUCALYPTUS study reached full b7 RO in blood and gut tissue, but not all patients Therefore, the evaluation of colonic CYP3A4 mRNA levels in the colons of patients with UC treated with etrolizumab is relevant in the context of potential DDI risk, given that the modulation of inflammatory activity in etrolizumab-treated UC is mainly localised to the colon. CYP3A substrate drugs appears to be low in UC patients. 77 To date, the potential treatment effect of etrolizumab on other CYP isoforms in IBD patients has not been evaluated.
| Immunogenicity assessment outcome for etrolizumab
In the phase I study, 2 of 38 etrolizumab-treated patients (5%) had detectable anti-drug antibodies (ADAs) that emerged after treatment. 
